Skip to content

Vivani Medical VANI Free cash flow

Free cash flow at other companies

Eli Lilly logo
Eli LillyLLY
$3.01B+1,828%
Amgen logo
AmgenAMGN
$1.48B+50.7%
Altimmune logo
AltimmuneALT
-$20.96M
Wave Life Sciences logo
Wave Life SciencesWVE
-$59.99M+5.1%
Prime Medicine logo
Prime MedicinePRME
-$42.92M+16.3%
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
-$27.99M+52.6%

Other financials

Income statement

See full
Revenue-
Gross profit$130.0K
Operating income-$6.8M-4.0%
Net income-$6.8M-7.6%
EPS (diluted)-$0.08+27.3%

Balance sheet

See full
Cash & equivalents$19.0M+57.7%
Total debt$18.3M-3.5%
Total equity$19.1M+64.2%
Total assets$42.4M+19.5%

Cash flow

See full
Operating cash flow-$6.2M-20.0%
CapEx$3.0K-40.0%

Valuation

See full
Market cap$106.93M+40.0%
Enterprise value$106.17M+19.3%

Profitability

See full
Gross margin36.3%
Operating margin-1,004.9%
Net margin-994.1%
FCF margin-832.3%

Returns & leverage

See full
Return on equity-176.4%+175pp
Debt / equity-0.7×
Current ratio3.2×+0.8×

Where this comes from

Calculated from Vivani Medical’s reported figures.

The official record: Vivani Medical’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vivani Medical's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vivani Medical's free cash flow?
Vivani Medical (VANI) reported free cash flow of -$6.2M in Q1 2026.
How has Vivani Medical's free cash flow changed year-over-year?
Vivani Medical's free cash flow decreased by 19.9% year-over-year, from -$5.17M to -$6.2M.
What is the long-term trend for Vivani Medical's free cash flow?
Over 3 years (2022 to 2025), Vivani Medical's free cash flow has grown at a 10.1% compound annual growth rate (CAGR), from -$19.13M to -$25.49M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.